4b1a: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of lysozyme with Keggin molecule== | |||
=== | <StructureSection load='4b1a' size='340' side='right' caption='[[4b1a]], [[Resolution|resolution]] 1.67Å' scene=''> | ||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4b1a]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Chick Chick]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4B1A OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4B1A FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=K3G:PHOSPHOMOLYBDATE+KEGGIN'>K3G</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | |||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Lysozyme Lysozyme], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.2.1.17 3.2.1.17] </span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4b1a FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4b1a OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4b1a RCSB], [http://www.ebi.ac.uk/pdbsum/4b1a PDBsum]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The complex fac-[Mo(CO)(3)(histidinate)]Na has been reported to be an effective CO-Releasing Molecule in vivo, eliciting therapeutic effects in several animal models of disease. The CO releasing profile of this complex in different settings both in vitro and in vivo reveals that the compound can readily liberate all of its three CO equivalents under biological conditions. The compound has low toxicity and cytotoxicity and is not hemolytic. CO release is accompanied by a decrease in arterial blood pressure following administration in vivo. We studied its behavior in solution and upon the interaction with proteins. Reactive oxygen species (ROS) generation upon exposure to air and polyoxomolybdate formation in soaks with lysozyme crystals were observed as processes ensuing from the decomposition of the complex and the release of CO. | |||
Characterization of a versatile organometallic pro-drug (CORM) for experimental CO based therapeutics.,Seixas JD, Mukhopadhyay A, Santos-Silva T, Otterbein LE, Gallo DJ, Rodrigues SS, Guerreiro BH, Goncalves AM, Penacho N, Marques AR, Coelho AC, Reis PM, Romao MJ, Romao CC Dalton Trans. 2012 Dec 7. PMID:23223860<ref>PMID:23223860</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
== | ==See Also== | ||
<references | *[[Lysozyme 3D structures|Lysozyme 3D structures]] | ||
[[Category: | == References == | ||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Chick]] | |||
[[Category: Lysozyme]] | [[Category: Lysozyme]] | ||
[[Category: Mukhopadhyay, A | [[Category: Mukhopadhyay, A]] | ||
[[Category: Romao, C C | [[Category: Romao, C C]] | ||
[[Category: Romao, M J | [[Category: Romao, M J]] | ||
[[Category: Silva, T S | [[Category: Silva, T S]] | ||
[[Category: Corm]] | [[Category: Corm]] | ||
[[Category: Hydrolase]] | [[Category: Hydrolase]] | ||
Revision as of 12:26, 21 December 2014
Crystal structure of lysozyme with Keggin moleculeCrystal structure of lysozyme with Keggin molecule
Structural highlights
Publication Abstract from PubMedThe complex fac-[Mo(CO)(3)(histidinate)]Na has been reported to be an effective CO-Releasing Molecule in vivo, eliciting therapeutic effects in several animal models of disease. The CO releasing profile of this complex in different settings both in vitro and in vivo reveals that the compound can readily liberate all of its three CO equivalents under biological conditions. The compound has low toxicity and cytotoxicity and is not hemolytic. CO release is accompanied by a decrease in arterial blood pressure following administration in vivo. We studied its behavior in solution and upon the interaction with proteins. Reactive oxygen species (ROS) generation upon exposure to air and polyoxomolybdate formation in soaks with lysozyme crystals were observed as processes ensuing from the decomposition of the complex and the release of CO. Characterization of a versatile organometallic pro-drug (CORM) for experimental CO based therapeutics.,Seixas JD, Mukhopadhyay A, Santos-Silva T, Otterbein LE, Gallo DJ, Rodrigues SS, Guerreiro BH, Goncalves AM, Penacho N, Marques AR, Coelho AC, Reis PM, Romao MJ, Romao CC Dalton Trans. 2012 Dec 7. PMID:23223860[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||